RudaCure, a bio-venture company developing treatments for intractable diseases, held a technology transfer agreement signing ceremony with Hanlim Pharmaceutical Co., Ltd., a mid-sized company developing domestic ophthalmic disease treatments, on the 13th for the corneal ulcer and corneal damage treatment RCI001U.
RCI001U is a pipeline derived from the existing dry eye disease treatment RCI001, and has demonstrated superior corneal damage healing effects compared to existing corneal treatments. Through this agreement, RudaCure provides Hanlim Pharmaceutical with domestic production and sales rights to the technology and receives milestone payments including clinical trial approvals.
Given the current absence of domestic drugs for corneal damage treatment, RudaCure's RCI001U is being transferred after completing third-party confirmatory efficacy testing along with non-clinical toxicology studies. It is expected that RudaCure and its strategic partner Hanlim Pharmaceutical will be able to respond swiftly to the corneal damage treatment market where drugs are currently absent.
RudaCure had already completed the domestic technology transfer of the dry eye disease treatment RCI001 to Hanlim Pharmaceutical in April 2021, and by executing this additional indication development agreement, the network between the two companies has been further strengthened. Going forward, it is expected that continuous collaboration will be pursued not only for dry eye disease and corneal damage treatments, but also for the development of various ophthalmic treatments including ocular implants for macular degeneration treatment.
메디팜헬스 http://www.medipharmhealth.co.kr/news/article.html?no=88169 헬스코리아 뉴스 https://www.hkn24.com/news/articleView.html?idxno=331344 메디파나 https://www.medipana.com/article/view.php?news_idx=307266&sch_cate=D팜뉴스 https://www.pharmnews.com/news/articleView.html?idxno=217143
헤럴드경제 http://news.heraldcorp.com/view.php?ud=20230116000105
메디소비자뉴스 http://www.medisobizanews.com/news/articleView.html?idxno=103851
데일리팜 http://www.dailypharm.com/Users/News/NewsView.html?ID=296092
약업신문 https://www.yakup.com/news/index.html?mode=view&cat=12&nid=277798
